NCT Number: NCT00092430
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
The purpose of this study is to demonstrate that an investigational refrigerated vaccine with measles, mumps, rubella, and varicella is well tolerated and has similar immune response when compared to a frozen vaccine with measles, mumps, rubella, and varicella.
Looking for future studies?
Notify MeKey information
Conditions
Age range
12 month–23 month
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy children 12-23 months of age
Exclusion criteria
- Previously had measles, mumps, rubella, or varicella
- Compromised immune system
Treatment and study plan
Primary outcomes
-
Percent of patients demonstrating adequate antibody titers 6 weeks following administration
Secondary outcomes
-
Geometric mean titers (GMT) 6 weeks post vaccination
Sponsors and collaborators
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Registry information
Official study title
A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children
Important dates
- Study start
- 2002
- Primary completion
- 2003
- Study completion
- 2003
- First posted
- Sep 27, 2004
- Registry last updated
- Nov 15, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
NCT00892775
Chickenpox, DNA Virus Infections
Singapore
View Trial DetailsSafety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
NCT01536405
Chickenpox, DNA Virus Infections
View Trial DetailsImmunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
NCT00578175
Chickenpox, DNA Virus Infections
Birmingham, Alabama, United States
View Trial DetailsImmunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
NCT01506193
Chickenpox, DNA Virus Infections
Rome, Lazio, Italy
View Trial Details